| Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Type/Product Area | Terms/Details (Date) |
| Ablynx NV* (Belgium) | Boehringer Ingelheim GmbH (Germany) | Agreement to develop Nanobodies against 10 targets | The €1.3B ($1.8B) deal includes €45M in committed funds, €30M over the research portion of the deal, and 125M in development milestone payments for each of the targets (9/7) |
| Acura Pharmaceuticals Inc. (OTC BB:ACUR) | King Pharmaceuticals Inc. | Agreement to develop and commercialize opioid analgesics using Acura's Aversion abuse-deterrent technology platform | King licensed Acura's Phase III pain drug Acurox and will pay $30M up front to Acura, research and development funding and up to $28M in milestone payments plus royalties for each of four products initially targeted in the deal (10/31) |
| Akebia Therapeutics Inc.* | Procter & Gamble Pharmaceuticals Inc. | Licensing agreement for oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to increase natural production of erythropoietin in anemic patients, and a first-in-class program targeting HPTP-beta phosphatase to stimulate angiogenesis in the treatment of peripheral artery disease | Akebia holds worldwide rights to both programs (9/14) |
| Amgen Inc. (AMGN) | Dompe Biotec SpA (Italy) | Amgen and Dompe combined commercial operations in Italy to form Amgen-Dompe, which will operate as an affiliate of Amgen | The newly formed business will be comprised of Amgen and Dompe staff plus current Amgen R&D staff in Italy (10/4) |
| Anacor Pharmaceuticals Inc.* | GlaxoSmithKline plc (UK) | Agreement for the discovery, development and commercialization of small-molecule, boron-based antivirals and antibacterials | Anacor will manage discovery and development through proof of concept; GSK will have an option to license eight candidates against four targets; it will pay Anacor $12M up front and make a $10M equity investment; Anacor also could receive milestones, ranging from $252M to $331M for each product, as well as tiered, double-digit royalties (10/8) |
| Antares Pharma Inc. (AMEX:AIS) | Undisclosed pharmaceutical company | Worldwide development and license agreement focused on a product in the field of opioid analgesia that will be delivered transmucosally using Antares' Easy-Tec oral disintegrating tablet delivery platform | Antares will receive an up-front payment, clinical and regulatory milestone payments and continued funding for development and technology transfer activities; Antares also will receive royalties (10/11) |
| Asuragen Pharmacogenomic Services (a unit of Asuragen Inc.*) | Merck & Co. Inc. | Research collaboration to develop a biomarker and pharmacogenomic test for cancer clinical trials | Asuragen will receive an undisclosed payment for the development of the test (10/23) |
| Asuragen Inc.* | Roche Molecular Systems Inc. (a unit of F. Hoffmann-La Roche Ltd.; Switzerland) | Licensing agreement for real-time quantitative PCR technology | Asuragen will use the technology for clinical gene expression profiling and DNA analysis in its clinical service programs (10/8) |
| BioLineRx Ltd.* (Israel) (TA: BLRX)(Israel) | Yeda Research and Development Company Ltd. | Worldwide exclusive license agreement to develop and commercialize BL-4050, a peptide for treating cancer | Financial terms were not disclosed (10/1) |
| BioMarin Pharmaceutical Inc. (BMRN) | Asubio Pharma Co. Ltd. (subsidiary of Daiichi Sankyo Co. Ltd.) | Licensing agreement for exclusive rights to data and intellectual property contained in the Kuvan new drug application | Asubio will use the data to supplement its current filing for approval in Japan of its BH4 product for the treatment of phenyl-ketonuria (9/17) |
| Bionas GmbH* (Germany) | Solvay Pharmaceuticals GmbH (Germany) | Service contract covering the metabolic profiling of several drug candidates identified in the context of Solvay's obesity research program | Financial details were not disclosed (10/1) |
| BioWa Inc.* | GlaxoSmithKline | Agreement for access to BioWa's Potelligent Technology platform for the development of antibody-dependent cellular cytotoxicity-enhanced antibodies | The agreement grants GSK nonexclusive rights to research and develop antibodies based on Potelligent Technology for an undisclosed number of targets; BioWa will receive an up-front payment and license fees (10/19) |
| BrainCells Inc.* | Taisho Pharmaceutical Co. Ltd. (Japan) | Licensing agreement to develop compounds for central nervous system indications, including mood disorders | Taisho retained rights to the program in Japan and China; BCI has rights in the rest of the world (9/27) |
| Celera Group (NYSE:CRA) | Merck & Co. Inc. | Research collaboration to develop biomarker and pharmacogenomic tests for cancer patients | Celera will evaluate the use of certain gene expression profiles identified by Merck, with the goal of developing diagnostic predictors for use in Merck's clinical trials; Celera will receive an undisclosed payment (9/17) |
| Cephalon Inc. (CEPH) | ECR Pharmaceuticals | Agreement to acquire North American rights to Amrix (cyclobenzaprine hydrochloride extended-release capsules), a muscle relaxant approved by the FDA | Cephalon is paying ECR $100M in cash for the rights; it will launch the product early in the fourth quarter (8/23) |
| Compugen Ltd. (CGEN) | Teva Pharmaceutical Industries Ltd. (Israel) | Agreement covering CGEN-54, a Compugen-discovered splice variant of MCP1 (monocyte chemoattractant protein 1) | The companies will collaborate on initial research, with Teva retaining an option for a worldwide exclusive development and commercialization license in exchange for milestones and royalties (8/28) |
| Convivia Inc.* | Raptor Pharmaceuticals Corp. | Agreement to acquire from Convivia various assets, including a product candidate targeting aldehyde dehydrog-enase deficiency | Further details were not disclosed (10/22) |
| Critical Outcome Technologies Inc. (UK; CDNX: COT) | Merck Serono (division of Merck KGaA; Germany) | Pilot project agreement to identify drug development candidates for an undisclosed oncology cellular target | Financial terms call for Merck to make a project commencement payment to COTI, and additional preclinical milestone payments (10/18) |
| Crucell NV (the Netherlands; CRXL) | Merck & Co. Inc. | Agreement under which Merck exercised an option for the exclusive use of Crucell's PER.C6 technology and an option for access to Crucell's AdVac vaccine technology in two infectious disease areas | Crucell acquires rights to certain cell-line technology developed by Merck for the manufacturing of recombinant proteins (9/10) |
| DARA BioSciences Inc.* | Bayer Pharmaceuticals Corp. | License agreement granting DARA exclusive worldwide rights to a series of patents and compounds for treating metabolic diseases, in particular Type II diabetes and dyslipidemia | DARA will develop and commercialize products while Bayer will receive an up-front payment, milestone payments and royalties during the development and commercialization; Bayer has certain rights to commercialize products (10/17) |
| Debiopharm Group SA* (Switzerland) | NanoCarrier Co. Ltd. (Japan) | Licensing agreement for ex-Japan development and commercialization rights to cancer drug DACH-Platin Polymeric Micelle | Debiopharm will provide DACH-platin starting material and pay NanoCarrier an up-front fee, milestone payments, manufacturing costs and royalties (10/31) |
| Draxis Health Inc. (Canada; DRAX) | Med Discovery SA (Switzerland) | Research agreement to use DraxImage's radio-pharmaceutical expertise to radiolabel Med Discovery's targeted protein therapeutics for cancer | Terms were not disclosed (8/22) |
| Dyax Corp. (DYAX) | Bayer Schering Pharma AG (Germany) | Agreement for the discovery of therapeutic antibodies | Dyax will identify therapeutic antibodies for two targets provided by Bayer, and Dyax will be allowed to work on additional targets and/or allow Bayer to exercise an option for an antibody library license (9/5) |
| Dynavax Technologies Corp. (DVAX) | Merck & Co. Inc. | Agreement to develop the Phase III hepatitis B virus vaccine Heplisav | The deal provides $31.5M up front, with $105M in potential milestone payments plus royalties (11/1) |
| Flamel Technologies SA (France; FLML) | Wyeth Pharmaceuticals | Agreement for development and licensing of a marketed protein to be delivered using Flamel's Medusa technology | Flamel will receive an up-front payment and potential development fees, milestones and royalty payments (9/12) |
| Galapagos NV (Belgium; BR:GLPG) | Janssen Pharmaceutica NV (unit of Johnson & Johnson) | Rheumatoid arthritis deal, involving up to 12 possible RA targets; the development component could involve up to seven targets | It could bring Galapagos $1.43B in up-front payments, license fees and milestones, and could involve as many as 15 to 19 targets (10/24) |
| GeneGo Inc.* | Bristol-Myers Squibb Co. | Licensing agreement for access to all major GeneGo products | BMS got access to various systems biology technology (9/25) |
| Gene Logic Inc. (GLGC) | Merck Serono (Switzerland) | Agreement for drug repositioning and development for several Merck Serono drug candidates that were discontinued for reasons other than safety | Gene Logic is entitled to success-based milestone payments, as well as royalties (8/28) |
| Gene Logic Inc. (GLGC) | Solvay Pharmaceuticals Inc. (Brussels) | Agreement for drug repositioning and development for multiple Solvay drug candidates that were discontinued or de-prioritized for reasons other than safety | Gene Logic is entitled to undisclosed mile-stone and royalty payments in the deal (8/27) |
| Genomatrix Software GmbH* (Germany) | Sanofi-Aventis (France) | Renewed license agreement for multisite access to Genomatrix microarray products | Terms of the deal were not disclosed (9/27) |
| Glenmark Pharmaceuticals Ltd.* (India) | Eli Lilly & Co. | Agreement for rights to Glenmark's TRPV1 antagonist molecules, including GRC 6211 | The deal is worth at least $350M, including a $45M up-front payment and $215M in development and sales milestones for the initial indication of pain; it also includes royalties, and up to $90M in additional milestones for other indications (10/30) |
| Halozyme Therapeutics Inc. (HALO) | Baxter International Inc. | Agreement to develop a subcutaneous version of Gammagard, an intravenous immune globulin product for primary immunodeficiency disorders | Halozyme will receive $10M up front, and potentially up to $111M in regulatory and sales milestones for each of the first three targets (9/10) |
| IDEA AG* (Germany) | Alpharma Inc. | Licensing agreement for exclusive U.S. rights to ketoprofen in Transfersome gel from IDEA | Terms include a $60M payment to IDEA at closing, along with $77M in potential clinical and regulatory milestone payments, and $45M or $65M on FDA approval (9/6) |
| ImClone Systems Inc. (IMCL) and Bristol-Myers Squibb Co. | Merck KGaA (Germany) | Collaboration to develop Erbitux in Japan | Once approved, Merck Serono Japan would distribute the product and record sales; Bristol-Myers and Merck would use their Japanese sales forces and would share profits and losses; Merck would receive 50% and ImClone and Bristol-Myers each would get 25%; ImClone also would receive a royalty equal to 4.75% of total net sales in Japan (10/17) |
| Immunicon Corp. (IMMC) | Merck Serono (Switzerland) | Laboratory service and assay development agreements | They cover laboratory service testing and development of specialized biomarker assays based on circulating tumor cells within the scope of an early clinical drug study (8/29) |
| Innovive Pharmaceuticals Inc. (OTC BB:IVPH) | TMRC Co. Ltd. | Agreement for Innovive to acquire exclusive European rights to develop and commercialize tamibarotene, a synthetic retinoid drug candidate | Innovive gained European rights to tamibarotene for acute promyelocytic leukemia, with an option to include other oncology disease areas; TMRC received an up-front fee and will be eligible for milestones and royalties (9/10) |
| Isis Pharmaceuticals Inc. (ISIS) | Ortho-McNeil Inc. (subsidiary of Johnson & Johnson) | Licensing agreement for two early stage, second-generation antisense drugs for diabetes | In exchange for worldwide development and marketing rights to ISIS 325568 and ISIS 377131, Ortho-McNeil agreed to pay Isis $45M up front, $15M in research funding over two years, up to $230M in development and regulatory milestone payments, and undisclosed royalties; the companies will work to discover two more new drugs, which could bring Isis another $150M in milestone payments (9/13) |
| ISTA Pharmaceuticals Inc. (ISTA) | Tanabe Seiyaku Co. Ltd. (Japan) | Licensing agreement for exclusive North American rights to nasal-dosage forms of bepotastine for treating allergy symptoms | ISTA will pay Tanabe $2M up front as well as potential milestone and royalty payments (9/27) |
| Keryx Bio-pharmaceuticals Inc. (KERX) of Japan Tobacco Inc.) | Torii Pharmaceutical Co. Ltd. (subsidiary | Agreement for Japanese rights to Keryx's Phase II phosphate binder, Zerenex | The deal is potentially worth $100M, with $20M coming near term; Torii also will pay royalties on Zerenex (9/26) |
| KineMed Inc.* | Merck Serono (Switzerland) | Collaboration to discover new applications for drug candidates | KineMed will identify new therapeutic uses in in vivo preclinical models by applying its translational medicine technologies; KineMed will receive an up-front payment, milestones and royalty payments in the deal (8/28) |
| Laboratorios Almirall SA*(Spain) | Shire plc (UK) | Definitive agreement to acquire a portfolio of eight marketed products along with their associated European sales teams | Almirall will pay Shire $213M for the products, which include Solaraze, Vaniqa, Lodine, Colazide, Cebutid, Meptid, Robaxin and Mintec (10/8) |
| MacroGenics Inc.* | Eli Lilly and Co. | Agreement worth more than $1B to develop and commercialize teplizumab | Lilly will acquire the exclusive rights to teplizumab, a drug being studied to treat Type I diabetes; MacroGenics will receive an up-front payment of $41M and $3M in other committed funds from Lilly; it also may receive up to $200M in development milestones for the Type I diabetes indication, and up to $250M in sales milestones, as well as double-digit royalties; milestones in additional indications could bring more than $600M to MacroGenics (10/18) |
| Medarex Inc. (MEDX) | Johnson & Johnson | Licensing arrangement under which Medarex will continue to allow Centocor to use its UltiMAb Human Antibody Development System | Medarex will receive license fees, potential milestone payments and royalties (9/5) |
| MedImmune Inc. (LSE:MDI) | GlaxoSmithKline plc (UK) | Licensing agreement for reverse genetics intellectual property to support the development and construction of new vaccine strains to produce non-live human influenza vaccines | MedImmune will receive an undisclosed up-front payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the technology (9/24) |
| MedImmune Inc. (unit of AstraZeneca plc; UK; LSE:MDI) | Novartis AG (Switzerland) | Licensing agreement for reverse genetics technology to Novartis | Novartis will use the technology to support development and construction of new vaccine strains to produce inactivated human seasonal, pre-pandemic and pandemic influenza vaccines (8/23) |
| Medivir AB (Sweden; SSE: MVIRB) | Guangdong Lantai-Viewland Pharmaceutical Co. Ltd. (China) and Beijing Mefuvir Medicinal Technology Co. Ltd. (China) | Agreement to transfer a license for the anti-HIV compound MIV-160 from Guangdong to Beijing Mefuvir | The company will develop MIV-160 for HIV prophylactic and therapeutic use; royalty rates remain the same, but Medivir has returned the right to obtain 4% ownership in Guangdong and instead receives an equivalent right to obtain a 5% ownership in Beijing Mefuvir (8/21) |
| Medivir AB (Sweden; SSE: MVIRB) | Hainan Noken Pharmaceutical Industry Ltd. (China) | Licensing agreement for the antiviral compound MIV-210 | Noken intends to develop MIV-210 as a pharmaceutical for the treatment of hepatitis B virus; Noken assumes responsibility for the clinical trials and has marketing rights in China, Hong Kong, Taiwan, Macao, Singapore, Japan, South Korea and Australia; Medivir retains marketing rights in other parts of the world; it may earn $7M in milestone payments and is entitled to a double-digit royalty on sales (9/4) |
| Microbia Inc.* | Forest Laboratories Inc. | Licensing agreement for the Phase IIb gastrointestinal drug linaclotide | The companies will split U.S. development and marketing costs as well as any profits, and Microbia stands to get royalties from sales in Mexico and Canada: it is potentially worth $330M for Microbia, including $70M up front (9/17) |
| Neurocrine Biosciences Inc. (NBIX) | Dainippon Sumitomo Pharma Co. Ltd. (Japan) | Licensing agreement for Japanese development and marketing rights to the insomnia compound indiplon | Neurocrine will receive an up-front payment of $20M and an additional $10M when Indiplon receives U.S. approval; it could earn up to another $100M if other milestones are met; the deal also includes double-digit royalties (11/1) |
| NitroMed Inc. (NTMD) | N30 Pharma | Licensing agreement covering the respiratory use of an s-nitrosothiol drug candidate | Financial terms were not disclosed (10/29) |
| NPS Pharmaceuticals Inc. (NPSP) | Nycomed (Switzerland) | Agreement for the first right to look at Phase III results of Gattex and enter a potential $185M agreement | The first right is in exchange for $10M to NPS; Nycomed will pay another $25M for the rights to the product in gastrointesintal indications outside North America; NPS also would be entitled to $150M in milestone payments, as well as double-digit royalties (9/26) |
| Pharmacopeia (PCOP) | Bristol-Myers Squibb Co. | Agreement for a selective androgen receptor modulator program, including PS178990 | Pharmacopeia agreed to provide its medicinal chemistry resources to a separate BMS discovery program for up to three years; Pharmacopeia also will pay BMS milestones associated with submission and approval of any therapeutic product for marketing, plus a stepped royalty rate on any product sales (10/15) |
| Protherics plc (UK; PTIL; LSE:PTI) | Myungmoon Pharma Co. Ltd.(Korea) | Licensing agreement for rights to develop anti-inflammatory products using Protherics' sustained-release ReGel delivery system | Protherics will receive a "small" up-front payment and royalties on any resulting sales in Korea (9/25) |
| Protherics plc (UK; PTIL; LSE:PTI) | Nobilon International BV (unit of Akzo Nobel NV; the Netherlands) | Licensing agreement for Protherics' CoVaccine HT adjuvant for use in pandemic influenza vaccines and seasonal influenza vaccines in the elderly | Nobilon gains exclusive global rights, excluding the U.S., to develop, manufacture and commercialize two new influenza vaccines containing CoVaccine HT; Protherics will receive an up-front payment and is eligible for milestone payments and royalties (9/26) |
| Protiva Biotherapeutics Inc.* (Canada) | Merck & Co. Inc. | Nonexclusive license agreement to Protiva's SNALP technology for research and development of therapeutics in the RNAi field | Protiva will receive a one-time payment from Merck with the potential for milestone and royalty payments (10/17) |
| Radius Health Inc.* | Novartis AG (Switzerland) | Option agreement for exclusive, worldwide rights to the Phase II osteoporosis drug BA058 outside Japan | If Novartis decides to move forward, Radius would receive an option-exercise payment as well as potential development, regulatory and commercial milestone payments that could bring in $500M (9/17) |
| Salix Pharmaceuticals (SLXP) | Wilmington Pharmaceuticals | Agreement for exclusive worldwide rights to metoclopramide-Zydis | Salix will make a small up-front payment, a regulatory milestone payment upon NDA approval and royalties on net sales (9/5) |
| Sapphire Therapeutics Inc.* | Novo Nordisk A/S (Denmark) | Licensing agreement for a discovery-stage ghrelin antagonist program | Financial terms were not disclosed (10/30) |
| Scolr Pharma Inc. (AMEX:DDD) | Dr. Reddy's Laboratories (India) | Collaboration and license agreement to pursue development and commercialization of an undisclosed oral prescription drug with potential for the cardio-pulmonary market | Dr. Reddy's will be responsbile for development, manufacturing and marketing, while Scolr will handle the formulation and assist with product scale-up activities (10/23) |
| SemBioSys Genetics Inc. (Canada; TSX:SBS) | AVAC Ltd. (Canada) | Agreement to develop Botaneco as an independent business | AVAC paid $2.4M in nondilutive funding to develop Botaneco as an independent entity; the funding will be paid over 27 months; Botaneco will provide AVAC a modest royalty on all gross revenues until two times the gross amount invested has been paid (10/17) |
| Sepracor Inc. (SEPR) | GlaxoSmithKline plc (UK) | Agreement covering the insomnia product Lunesta in Europe and elsewhere | Sepracor is entitled to a $20M up-front payment in the deal and up to $135M more in potential milestone payments, as well as escalating double-digit royalties on resulting sales; GSK has rights everywhere but the U.S., where Sepracor already sells the product (9/11) |
| Summit Corp. plc* (UK) | Undisclosed pharmaceutical company | Agreement for the use of Summit's zebrafish technology | The deal is worth $450,000 and involves the assessment of compounds in a range of organs that are conserved between the zebrafish and the humans (10/30) |
| Synta Pharmaceuticals Corp. (SNTA) | GlaxoSmithKline plc (UK) | Partnership to develop and commercialize a product for metastatic melanoma | The companies will share U.S. responsibility for STA-4783; GSK will hold rights everywhere else; total value could be more than $1 billion (10/10) |
| Theratechnol-ogies Inc. (Canada; TSX:TH) | OctoPlus NV (the Netherlands) | Exclusive worldwide rights to develop and commercialize its glucagon-like peptide-1 portfolio of analogues for the treatment of diabetes and other potential indications | Theratechnologies received an undisclosed up-front payment in the deal, and is eligible to receive up to €36M ($51M) in milestone payments, as well as royalties (9/27) |
| Tolerx Inc.* | GlaxoSmithKline plc (UK) | Agreement to develop and commercialize otelixizumab | Tolerx has the option to co-promote it in Type I diabetes in the U.S.; GSK has the exclusive rights to develop and commercialize the antibody in all other indications worldwide; Tolerx will receive an up-front payment, equity and advance R&D funding totaling $70M; it may receive up to $155M in future development costs, and another $350M in milestone payments; it also is entitled to $175M in sales milestone payments and tiered, double-digit royalties (10/23) |
| Verus Pharmaceuticals Inc.* | AstraZeneca plc | Agreement for AstraZeneca to acquire Verus' pediatric asthma development programs | Verus is to receive an up-front payment of $30M, development expense reimbursements and a potential earn-out payment of $280M (9/24) |
| ViaCell Inc. (VIAC) | EMD Serono Inc. (an affiliate of Merck KGaA; Germany) | Agreement to support the clinical development of ViaCyte | Financial terms were not disclosed (9/4) |
| Vitae Pharmaceuticals Inc.* | Boehringer Ingelheim GmbH (Germany) | Partnership to develop 11beta-HSD1 inhibitors for diabetes and other metabolic diseases | Vitae will get $36.5M in up-front fees, equity investments and research funding, plus the chance to earn up to $300M in milestones; Vitae also will be eligible for royalties (10/15) |
| Vivalis (France; PARIS:VLS) | Innate Pharma SAS (France; PARIS:IPH) | Collaboration to evaluate Vivalis' EBx cell lines, derived from avian embryonic stem cells, for the production of monoclonal antibodies | Innate will compare production of its monoclonal antibody in EBx and CHO cells, looking at the glycosylation profile and cytotoxic activity (9/12) |
| Vivalis (France; PARIS:VLS) | Sanofi-Aventis SA (France) | Agreement to evaluate Vivalis' EBx cell lines, cell substrates derived from avian embryonic stem cells, from the production of monoclonal antibodies | Financial terms were not disclosed (10/17) |
| Xceleron Ltd.* (UK) | Organon A/S cell expression technology (the Netherlands; unit of Akzo Nobel) | Collaboration on a three-compound human microdose study focusing on candidate selection for further clinical development | Xceleron will use its Accelerator MassSpectrometry technology to determine human plasma concentrations after microgram administration of the drug candidates (9/10) |
| XenoPort (XNPT) | Xanodyne Pharmaceuticals Inc. | Partnership for a preclinical candidate for menorrhagia | Xanodyne picked up U.S. rights to develop and commercialize XP21510; XenoPort will receive an up-front cash payment of $12M and milestones of up to $130M; the firm also could receive $5M in milestones related to Xanodyne's XP12B and tiered, double-digit royalty payments on any future sales of XP21510, as well as escalating single-digit royalties on future sales of XP12B (10/15) |
| XOMA Ltd. (XOMA) | Pfizer Inc. | License agreement that provides Pfizer with non-exclusive, worldwide access to XOMA's patented bacterial cell expression technology | XOMA gets a $30M up-front cash payment; the deal also calls for Pfizer to pay XOMA undisclosed fees and milestones, as well as potential royalties (8/28) |
|
Notes: # The information in the chart does not cover agricultural agreements or those between biotech companies. * Private companies are indicated with an asterisk. ** Denotes the date the item ran in BioWorld International.Unless otherwise noted, stock symbols listed are on the Nasdaq market. AMEX = American Stock Exchange; BR = Brussels Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange. TA = Tel Aviv Stock Exchange | |||
To read more on related topics, click on one of the words below.